



Peptic Ulcer Disease; Stomach and Gastric Ulcers, a Concise Review

Ahtshamullah Chaudhry ^{a*}, Kimberly Morton Cuthrell ^b
and Owen R Thornton ^c

^a St. Dominic Hospital, Jackson, Mississippi, United States.

^b Saint James School of Medicine, United States.

^c University of North Carolina at Chapel Hill, United States.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/96884>

Review Article

Received: 21/12/2022

Accepted: 27/02/2023

Published: 01/03/2023

ABSTRACT

The most prevalent condition affecting the stomach and duodenum is peptic ulcer disease (PUD), which is linked to *Helicobacter pylori* (*H. pylori*) infection. Esophageal, duodenal, and stomach ulcers are all parts of peptic ulcer disease (PUD). Epigastric discomfort is the PUD symptom that commonly occurs. Proton Pump Inhibitors (PPI), Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), and antibiotics are widely used to treat PUD, which is caused by an imbalance between offensive and defensive forces. Abdominal discomfort, nausea, vomiting, weight loss, and bleeding or perforation with the complicated disease are only a few of the symptoms of peptic ulcer disease. Understanding the methodology behind diagnosis and treatment options requires identifying the risk factors and mechanisms that result in PUD. The purpose of this review is to provide a concise summary of key ideas and recent findings in the field of peptic ulcer disease management, etiology, pathophysiology, and epidemiology.

*Corresponding author: E-mail: Ahtsham_87@gmail.com;

Keywords: Ulcer disease; stomach; gastric ulcers; proton pump inhibitors (PPI).

1. INTRODUCTION

A peptic ulcer or stomach ulcer is defined as deep damage of the mucosa or lining of the stomach and/or duodenum that extends past the muscular mucosa, specifically to the muscle layer, as a result of the production of gastric acid in the environment. The use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which naturally include the Acetylsalicylic acid (ASA), and chronic *Helicobacter-pylori* (*H. pylori*) infection are the two most common etiological antecedents. There are specific, less common, and thought out combined antecedents that can result in a peptic ulcer PU, accounting for less than 5% of occurrences. One of these is Zollinger-Ellison syndrome (ZES), also known as gastronomy. ZES is a neuroendocrine tumor that is hyperactive and gastrinsecretory and is frequently seen near the head of the pancreas or in the duodenal wall [1]. Acid-induced lesions called peptic ulcers affect the stomach and duodenum and are distinguished by denuded mucosa with the defect extending into the submucosa or muscularis propria. Erosion is the term for lesions that do not extend to this depth [2]. Erosions are larger than 5 mm in diameter and represent a breach in the mucosal barrier of the stomach lining that penetrates the muscularis mucosa. An important fact to consider is that this illness process can be both prevented and treated. Depending on the cause of the patient's stomach ulcer, numerous treatment options may be available. The stomach mucosa is naturally shielded by the body from the potentially dangerous gastric lumen's acidic environment. When these defenses are compromised, the stomach mucosa may undergo changes that finally result in erosion and ulceration. Prostaglandins, mucus, growth factors, and proper blood flow all work to protect the gastric mucosa. Smoking, hydrochloric acid, ischemia, NSAIDs, hypoxia, alcohol, and *Helicobacter pylori* (*H. pylori*) are known to harm this barrier [3].

The risk of numerous gastroduodenal illnesses, including gastric atrophy with intestinal metaplasia, peptic ulcer disease (PUD), ulcer bleeding, and gastric cancer, is said to increase with age [4]. Unknown antecedents or painful sores that appear to develop spontaneously are used to define the unknown origin of peptic ulcer illnesses. Acid-induced lesions known as peptic ulcers cause denuded mucosa in the stomach

and duodenum, with the defect extending into the submucosa or muscularis propria. Erosion is the term for lesions that do not extend to this depth [5]. One of the most common diseases in the globe, PUD has contributed significantly to both morbidity and mortality through some of its consequences. The prevalence of duodenal and gastric ulcers varies across the global population, and the average age of those who have the condition is between 30 and 60 years old, while it can strike at any age. Among Africa, duodenal ulcers are uncommon in black individuals, but in the United States, all individuals experience the same prevalence of duodenal ulcers. Additionally, males are more likely than females to get duodenal ulcers [6-8].

The causes of peptic ulcers might be complicated. Alcohol and nicotine, for example, can prevent or lessen the release of mucus and bicarbonate, which increases the discharge of acid. Children of parents with duodenal ulcers are three times more likely to develop ulcers than the general population [9], suggesting that genetic factors can have an impact. The discovery of *H. pylori* and ulcers linked to long-term anti-inflammatory drug usage has improved our understanding of the circumstances surrounding the development of peptic ulcers [10].

2. EPIDEMIOLOGY

In 1990, 10% of Americans reported having peptic ulcer disease, and there are over 500,000 new cases identified each year in the United States [4]. However, globally, the risk of mortality and the requirement for hospitalization as a result of PUD has been declining. Due to treatment and better hygiene, *H. pylori* infections have certainly decreased, which is the most likely secondary cause of PUD. This trend may also be partially explained by rising prescription and over-the-counter use of acid-suppressing pharmaceuticals as well as increased caution when using non-steroidal anti-inflammatory drugs (NSAIDs) [3,11,12]. Peptic ulcer disease, which includes gastric ulcers, has a lifetime prevalence of 5–10% of individuals, which is probably an underestimate of the condition because some people may experience no symptoms. According to studies, the likelihood of developing stomach ulcers rises with age and NSAID use frequency. According to research, smoking increases the relative risk of developing stomach ulcers by two

times compared to non-smokers. The prevalence of stomach ulcers is the same for both men and women. In the United States of America's population, the frequency of *H. pylori* infection at age 60 is close to 50%. According to estimates, 25% of long-term NSAID users will get stomach ulcers [13].

3. ETIOLOGY

The two most frequent causes of stomach ulcers are gastric prostaglandin loss brought on by non-

steroidal anti-inflammatory drugs and *H. pylori* bacterium infection. Hypergastrinemia (Zollinger-Ellison syndrome), viral infections like Cytomegalovirus CMV, chemotherapy, radiation, gastric outlet blockage, gastric infiltrative illnesses like malignancy, smoking, and Crohn's disease are some of the less frequent etiologies.

All of these etiologies share the trait of encouraging a breach in the mucosal barrier, which exposes the gastric mucosa to the harmful effects of acid [16,17].




Fig. 1. Incidence of different ulcer types [14]




Fig. 2. Gender wise incidence of peptic ulcers [15]




Fig. 3. Rough Estimates of Conditions Associated With stomach Ulcers (Kayali et al. 2018)




Fig. 4. Causes of stomach Ulcer Disease [18]

4. PATH-PHYSIOLOGY

The injury determines the pathophysiology of stomach ulcer formation. A thorough explanation will concentrate on each since NSAID use and/or H. pylori infection cause 80 to 90% [19] of stomach ulcers, respectively. First, focusing on H. pylori, which colonize 45–50% of the stomach mucosa globally. People get immunized against

this bacterium at a young age, particularly in developing nations with lower socioeconomic levels and crowded households. In the host, these bacteria cause an inflammatory reaction that results in an epithelial reaction, degeneration, and damage, which is known as gastritis. Patients who have this illness typically develop pan-gastritis. Due to the damage to the antral somatostatin release, increased gastrin

secretion and thus higher acid generation result. Patients with the germs still present in the antrum eventually develop stomach ulcers. The more proximal stomach body's parietal cells still have full production capacity, preventing the creation of ulcers there. Not all individuals with this infection experience symptom which depends on the virulence of the bacteria and other host risk factors. The development of *cagA*, which causes greater cytokine cell death and mucosal injury, is a typical bacterial virulence factor [20-22].

The second most frequent cause generating stomach ulcers is NSAID medicines. When compared to persons who do not take these medications, patients who do have a relative risk of four for stomach ulcers. NSAIDs can cause ulceration through a variety of different methods. When exposed to gastric acid, the medications themselves are weak acids. They persist in the epithelial cells and increase cellular permeability, which causes actual damage to the cells. The reduction in prostaglandin synthesis is the main cause of NSAID-induced ulceration. NSAIDs prevent the cyclooxygenase-1 enzyme from

increasing prostaglandin synthesis, which in turn promotes the secretion of gastric bicarbonate, the formation of mucus barriers, an increase in mucosal blood flow, and an expedited rate of epithelial cell restitution and repair following damage or cell death. Overall, the decrease in gastric blood flow and the mild ischemia it generates in the stomach mucosa are what cause the most detrimental physiological damage. The pathophysiology of gastric ulcer development mostly varies on the etiology, but they all result in the destruction or loss of the integrity of the stomach mucosa [23-30].

5. SIGNS AND SYMPTOMS

Depending on the location of the disease and age, the signs and symptoms of peptic ulcer disease can change. Differentiating between gastric and duodenal ulcers depends on when they first manifest themselves in relation to meals. Duodenal ulcers commonly cause nighttime pain. People who have a gastric outlet obstruction frequently describe having a bloated or full abdomen in the past [31-35].




Fig. 5. Flow chart model showing signs and symptoms

6. DIAGNOSIS

When patients exhibit symptoms such as epigastric stomach discomfort, burning, postprandial fullness, or early satiety, the diagnosis is initially made based on clinical suspicion. Traditionally, individuals with duodenal ulcers report stomach pain that worsens when they are hungry, two to three hours after eating, or at night. In contrast, people with stomach ulcers describe post-meal abdominal pain, nausea, and vomiting. Elderly people frequently have minor symptoms, and some PUD patients who have not received treatment may experience intermittent symptoms due to spontaneous healing before relapsing as a result of persistent risk factors including ongoing use of NSAIDs or *H. pylori* infection [24,36-39].

Anti-secretory therapy may be initiated as an empiric course of treatment if the clinical symptoms point to a potential peptic ulcer illness and no alarm signals are present. In addition, because *H. pylori* is a common cause of PUD, a test-and-treat strategy using a non-invasive *H. pylori* test (stool antigen or urea breath test) is advised for patients under the age of 55 who do not have any alarming symptoms, in areas where gastric cancer is uncommon and the prevalence of *H. pylori* is higher than 20%, and in patients who have no alarming symptoms elsewhere [40]. Endoscopy is advised to make a diagnosis in older patients and those with warning symptoms. Gastrointestinal (GI) bleeding, early satiety, weight loss, dysphagia or odynophagia, a family history of upper GI cancer, iron deficiency anemia, or new upper GI symptoms in patients over 55 are alarming symptoms [41]. The most accurate way to diagnose PUD is through an upper endoscopy or esophagogastroduodenoscopy (EGD). Gastric biopsies can be done to detect *H. pylori* and also rule out cancer [30,42-44].

Table 1. Diagnosis tests

Diagnostic options	Accuracy	References
Urea Breath Test	95%	[45]
Serology	82-95%	[13]
Fecal antigen testing	95%	[46,47]
Rapid urease test	98%	[47,48]
Histology	>90%	[48]
Culture	>80%	[48]

7. TREATMENT OPTIONS

Antisecretory medications for peptic ulcer disease include proton pump inhibitors and H2-

receptor antagonists (PPIs). Due to PPIs' greater healing and efficacy, H2 receptor blockers have mostly been supplanted. PPIs suppress the stomach's ability to produce acid, relieving symptoms and accelerating recovery. Given that long-term PPI use raises the risk of bone fractures, treatment may include calcium supplements. Stopping the usage of NSAIDs or switching to a lower dose helps alleviate NSAID-induced PUD. Long and short-term discontinued usage of corticosteroids, bisphosphonates, and anticoagulants is best as well. .. Misoprostol, a prostaglandin analog, is occasionally used as a preventative measure for NSAID-induced peptic ulcers [49, 50].

A triple antibiotic, proton pump inhibitor, and *pylori*-inducing PUD therapy combination is the first line of defense. For 7 to 14 days, patients take pantoprazole, clarithromycin, metronidazole, or amoxicillin. PPIs and antibiotics cooperate to destroy *H. pylori*. The antibiotic chosen should take into account the existence of environmental antibiotic resistance. Quadruple therapy, which uses bismuth and several antibiotics, is used if first-line therapy is unsuccessful [3, 51, 52].

When a patient is unresponsive to medicinal therapy, noncompliant with the treatment regimen, or at a high risk of consequences, surgical intervention may be recommended. Over 5 mm in diameter peptic ulcers that do not cure after 8–12 weeks of PPI medication are referred to as refractory peptic ulcers. Consistent *H. pylori* infection, continued NSAID usage, serious comorbidities that hinder ulcer healing, or other disorders such as gastrinoma or stomach cancer are the usual causes. Patients may be candidates for surgical therapy if the ulcer still exists despite considering the aforementioned risk factors. Vagotomy and partial gastrectomy are two surgical alternatives [12,53-59].

7.1 Efficiency of Herbal Products in Peptic Ulcers

The use of herbal remedies along with conventional antigastric ulcer medications may have a synergistic effect in the fight against *H. pylori* and gastric ulcer disease and enhance the prognosis for patients with gastric ulcers. More clinical research should be carried out with bigger sample sizes on the efficacy and safety of medicinal plants with antiulcer activity because there are so few human studies available. Designing studies to look into and clarify the mechanisms of action of medicinal plants used in




Fig. 6. Management options [60]

the treatment or prevention of peptic ulcers would also be beneficial [11, 61-64].

Last but not least, herbal items used for medical purposes need to be licensed to improve their safety and quality and guarantee that randomized controlled studies support claims of their potential usefulness. Despite an increase in reports of herb-drug interactions, there still exists inadequate studies in this area and no steps have been done to rectify the lack of literature. Because of this, pharmacists and doctors in particular should be aware of the dangers related to the use of herbal medicines, whether alone or in conjunction with other herbal or conventional standard therapy [36, 65, 66].

8. CONCLUSIONS

Due to the drop in *H. pylori* infections, better accessibility to antisecretory medication, and more prudent NSAID use, PUD is a disease with a declining clinical burden. Due to its persistently high lifetime frequency and variable clinical presentation, PUD must be recognized and managed properly to prevent and limit serious problems. When assessing PUD, it is important to test for and treat *H. pylori* as well as prevent mucosal damage brought on by NSAIDs (either by concomitant PPI prophylaxis or by selecting COX-2 selective NSAIDs, if available). The most frequent consequence, PUD hemorrhage, is treated with resuscitation, anti-secretory medication, endoscopy, and administration of antithrombotic medicines.

CONSENT AND ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Sanad MH, Saleh GM, Marzook FA. Radioiodination and biological evaluation of nizatidine as a new highly selective radiotracer for peptic ulcer disorder detection. *J Labelled Comp Radiopharm.* 2017;60(13):600-607.
2. Feldman M, Friedman LS, Brandt LJ. *Sleisenger and Fordtran's gastrointestinal and liver disease E-book: pathophysiology, diagnosis, management.* Elsevier Health Sciences; 2020.
3. Lanas A, Chan FK. Peptic ulcer disease. *The Lancet.* 2017;390(10094):613-624.
4. Sonnenberg A, Everhart JE. The prevalence of self-reported peptic ulcer in the United States. *Am J Public Health.* 1996;86(2):200-5.
5. Ramakrishnan K, Salinas RC. Peptic ulcer disease. *Am Fam Physician.* 2007; 76(7):1005-12.
6. Nieto YB. Protocolo terapéutico de la úlcera péptica. *Medicine-Programa de Formación Médica Continuada Acreditado.* 2012;11(3):179-182.

7. Sung JJ, et al. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. *Am J Gastroenterol.* 2010;105(1): 84-9.
8. Martins LC, et al. Soroprevalência de anticorpos contra o antígeno CagA do *Helicobacter pylori* em pacientes com úlcera gástrica na região Norte do Brasil. *Revista da Sociedade Brasileira de Medicina Tropical.* 2002;35:307-310.
9. Lafortuna CL, et al. The relationship between body composition and muscle power output in men and women with obesity. *J Endocrinol Invest.* 2004; 27(9):854-61.
10. Toneto MG, Oliveira FJM, Lopes MHI. Evolução histórica da úlcera péptica: da etiologia ao tratamento. *Scientia Medica.* 2011;21(1):23-30.
11. Sonnenberg, A, Review article: historic changes of *Helicobacter pylori*-associated diseases. *Aliment Pharmacol Ther.* 2013;38(4):329-42.
12. Lanás-Gimeno A, Lanás A. Risk of gastrointestinal bleeding during anticoagulant treatment. *Expert Opin Drug Saf.* 2017;16(6):673-685.
13. Kayali S, et al. *Helicobacter pylori*, transmission routes and recurrence of infection: state of the art. *Acta Biomed.* 2018;89(8-s):72-76.
14. Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. *J Multidiscip Healthc.* 2014;7:137-46.
15. Johnson Alegbeleye B. A modified open omental plugging of peptic ulcer perforation in a mission hospital, northwestern cameroon. *Journal of Clinical Investigation and Studies.* 2019; 2(1).
16. Papatheodoridis GV, Archimandritis AJ. Role of *Helicobacter pylori* eradication in aspirin or non-steroidal anti-inflammatory drug users. *World J Gastroenterol.* 2005;11(25):3811-6.
17. Zhang BB, et al. Association between vacA genotypes and the risk of duodenal ulcer: a meta-analysis. *Molecular Biology Reports.* 2014;41:7241-7254.
18. Ayoub F, et al. Once versus twice-daily oral proton pump inhibitor therapy for prevention of peptic ulcer rebleeding: A propensity score-matched analysis. *Gastroenterology Res.* 2018; 11(3):200-206.
19. Chey WD, Wong BC. American college of gastroenterology guideline on the management of *Helicobacter pylori* infection. *Am J Gastroenterol.* 2007;102(8):1808-25.
20. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. *Am J Gastroenterol.* 2009;104(3):728-38.
21. Huang JQ, Sridhar S, Hunt RH. Role of *Helicobacter pylori* infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. *Lancet.* 2002;359(9300):14-22.
22. Lanás Á, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. *Clin Gastroenterol Hepatol.* 2015;13(5):906-12.e2.
23. Somasundaram S, et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. *Aliment Pharmacol Ther.* 2000;14(5):639-50.
24. Masclee GM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. *Gastroenterology.* 2014;147(4):784-792.e9; quiz e13-4.
25. Crooks CJ, West J, Card TR. Comorbidities affect risk of nonvariceal upper gastrointestinal bleeding. *Gastroenterology.* 2013;144(7):1384-93, 1393.e1-2; quiz e18-9.
26. González-Pérez, A, et al. Risk factors associated with uncomplicated peptic ulcer and changes in medication use after diagnosis. *PLoS One.* 2014;9(7): e101768.
27. Chey WD, et al. ACG clinical guideline: treatment of *Helicobacter pylori* infection. *Official Journal of the American College of Gastroenterology* | ACG. 2017;112(2):212-239.
28. Kanno T, et al. Accommodation in a refugee shelter as a risk factor for peptic ulcer bleeding after the Great East Japan Earthquake: a case-control study of 329 patients. *J Gastroenterol.* 2015;50(1):31-40.
29. Kiss, S, et al, *Helicobacter*-negative gastritis: polymerase chain reaction for *Helicobacter* DNA is a valuable tool to elucidate the diagnosis. *Alimentary*

- Pharmacology & Therapeutics. 2016;43(8):924-932.
30. McColl KE. *Helicobacter pylori*-negative nonsteroidal anti-inflammatory drug-negative ulcer. *Gastroenterol Clin North Am.* 2009;38(2):353-61.
 31. El-Omar EM, et al. *Helicobacter pylori* infection and chronic gastric acid hyposecretion. *Gastroenterology.* 1997; 113(1):15-24.
 32. Moss, S.F, et al, Effect of *Helicobacter pylori* on gastric somatostatin in duodenal ulcer disease. *Lancet,* 1992;340(8825):930-2.
 33. Bhala N. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet,* 2013;382(9894):769-79.
 34. Bjarnason I, et al. Determinants of the short-term gastric damage caused by NSAIDs in man. *Aliment Pharmacol Ther.* 2007;26(1):95-106.
 35. Mössner J. The indications, applications, and risks of proton pump inhibitors. *Dtsch Arztebl Int.* 2016;113(27-28):477-83.
 36. Huang JQ, Sridhar S, Hunt RH. Role of *Helicobacter pylori* infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. *The Lancet.* 2002;359(9300):14-22.
 37. Charpignon C, et al. Peptic ulcer disease: one in five is related to neither *Helicobacter pylori* nor aspirin/NSAID intake. *Alimentary Pharmacology & Therapeutics.* 2013;38(8):946-954.
 38. Levenstein S, et al. Psychological stress increases risk for peptic ulcer, regardless of *Helicobacter pylori* infection or use of nonsteroidal anti-inflammatory drugs. *Clinical Gastroenterology and Hepatology.* 2015;13(3):498-506. e1.
 39. McColl KE. *Helicobacter pylori*-negative nonsteroidal anti-inflammatory drug-negative ulcer. *Gastroenterology Clinics of North America.* 2009;38(2):353-361.
 40. Agréus L, Talley NJ, Jones M. Value of the "test & treat" strategy for uninvestigated dyspepsia at low prevalence rates of *Helicobacter pylori* in the population. *Helicobacter.* 2016;21(3):186-191.
 41. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. *Gastroenterology.* 2005;129(5):1756-80.
 42. Siddique O, et al. *Helicobacter pylori* infection: An Update for the internist in the age of increasing global antibiotic resistance. *Am J Med.* 2018;131(5):473-479.
 43. Hooi JKY, et al. Global prevalence of *Helicobacter pylori* infection: Systematic Review and meta-analysis. *Gastroenterology.* 2017;153(2):420-429.
 44. Zaki M, et al. *H. pylori* acutely inhibits gastric secretion by activating CGRP sensory neurons coupled to stimulation of somatostatin and inhibition of histamine secretion. *Am J Physiol Gastrointest Liver Physiol.* 2013;304(8):G715-22.
 45. Scida S, et al. Relationship between *Helicobacter pylori* infection and GERD. *Acta Biomed.* 2018;89(8-s):40-43.
 46. Barchi A, et al. A non-invasive method for the diagnosis of upper GI diseases. *Acta Biomed.* 2018;89(8-s):40-43.
 47. Graham DY, Lu H, Dore MP. Relative potency of proton-pump inhibitors, *Helicobacter pylori* therapy cure rates, and meaning of double-dose PPI. *Helicobacter.* 2019; 24(1):e12554.
 48. Buysse T, Kotwal V. Gastric outlet obstruction caused by a duodenal clot. *Cureus.* 2022;14(3):e22814.
 49. Malfertheiner P, et al. Management of *Helicobacter pylori* infection-the maastricht V/Florence consensus report. *Gut.* 2017;66(1):6-30.
 50. Park JY, et al. *Helicobacter pylori* clarithromycin resistance and treatment failure are common in the USA. *Dig Dis Sci.* 2016;61(8):2373-2380.
 51. Lanas AI, et al. Risk factors associated with refractory peptic ulcers. *Gastroenterology.* 1995; 109(4):1124-33.
 52. Lanas A, et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. *Aliment Pharmacol Ther.* 2011;33(5):585-91.
 53. Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: A comprehensive review. *Gut Liver.* 2017; 11(1):27-37.
 54. Stanley AJ, et al. Multicentre comparison of the glasgow blatchford and rockall scores in the prediction of clinical end-points after upper gastrointestinal haemorrhage. *Aliment Pharmacol Ther.* 2011;34(4):470-5.
 55. Villanueva C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. *N Engl J Med.* 2013;368(1):11-21.
 56. Laine L, Jensen DM. Management of patients with ulcer bleeding. *Official*

- Journal of the American College of Gastroenterology| ACG. 2012;107(3):345-360.
57. Sachar H, Vaidya K, Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med. 2014;174(11):1755-62.
 58. Wang CH, et al. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2010;170(9):751-8.
 59. Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107(3):345-60; quiz 361.
 60. Lanas A, Chan FKL. Peptic ulcer disease. The Lancet. 2017;390(10094):613-624.
 61. Kuna L, et al. Peptic Ulcer disease: a brief review of conventional therapy and herbal treatment options. Journal of Clinical Medicine. 2019;8(2):179.
 62. Søreide K, et al. Perforated peptic ulcer. The Lancet. 2015;386(10000):1288-1298.
 63. Zhang BB, et al. Association between vacA genotypes and the risk of duodenal ulcer: a meta-analysis. Mol Biol Rep. 2014;41(11):7241-54.
 64. De DD, Roychoudhury S. To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastroduodenal diseases. World Journal of Gastroenterology: WJG. 2015;21(10):2883.
 65. Lanas Á, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clinical Gastroenterology and Hepatology. 2015;13(5):906-912. e2.
 66. Masclee GM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014;147(4):784-792. e9.

© 2023 Chaudhry et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/96884>